Effect of High Dose Intravenous Vitamin C in Severe Pneumonia

Pneumonia Clinical Trial

— VICSEP  

Official title:

Effect of High Dose Intravenous Vitamin C as an Adjunct in the Treatment of Patients With Severe Pneumonia in Intensive Care Unit: a Multi-center, Double-blinded, Two-arm, Placebo-controlled, Randomized Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05842382
• Other study ID #: VICSEP
• Status: Recruiting
• Phase: Phase 2
• Start date: January 12, 2024
• Est. completion date: February 2026

Study information

• Verified date: June 2024
• Source: Clinical Research Centre, Malaysia
• Contact: Calvin Wong Ke Wen, MBBS MRCP
• Phone: +6082276 666
• Email: vicsep.my[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is a multicenter, randomized, double-blind, two-arm, parallel-group, placebo-controlled trial to investigate the effect of high dose intravenous (IV) Vitamin C as an adjunct to the standard of care for patients with severe pneumonia versus placebo in ICU.

Description:

Subjects will be randomized 1:1 to receive either high dose IV Vitamin C (12g/day) or placebo, every 6 hourly, until successful extubation (minimum 16 doses, maximum 40 doses). Placebo will be the equivalent volume of dextrose 5% given intravenously. Active drug or placebo will be prepared in a sterile method by designated personnel at each site. Active drug or placebo will be prepared in a 50cc syringe and infusion tubing attached, where both are coloured and UV-protected. The recruitment period is expected to be 24 months. Phone call follow-up will be conducted at day 60 (+7 days) post-randomization to review subjects' activities of daily living. All data will be entered electronically into REDCap.

All randomized subjects will be included in the intention-to-treat analysis (ITT) dataset for primary and secondary efficacy endpoints analyses. Safety analysis will be conducted for all subjects who received at least one dose of study drug. There are no interim analyses planned in this trial. At least one safety review will be conducted at 50% target recruitment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 484
• Est. completion date: February 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who are aged 18 and above

• Patients who are diagnosed with severe pneumonia

• Patients who are mechanically ventilated

Exclusion Criteria:

• Known allergy to Vitamin C

• Pregnancy

• Known history of ongoing concomitant infection

• Participation in another clinical trial and/or receipt of investigational drugs within 4 weeks prior to enrollment

• Moribund patient with multiorgan failure to the judgement of the treating physician, who is not expected to survive 24 hours

• Patient who requires home oxygen therapy or mechanical ventilation, including tracheostomy or non-invasive ventilation, except for CPAP/BIPAP for sleep-disordered breathing

• Known history of previous or current diagnosis of renal stones

• Known diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency

• Known diagnosis of hemochromatosis

• Known diagnosis of poorly controlled chronic pulmonary disease, including:

• Chronic obstructive pulmonary disease with oxygen therapy

• Chronic restrictive pulmonary disease with oxygen therapy

• Bronchial asthma on Step 5 of treatment ladder as shown in Pocket Guide for Asthma Management and Prevention

• Lung cancer in Stage IV of disease

• Known diagnosis of heart failure on anti-failure treatment or requiring mechanical hemodynamic support (e.g. LVAD), with recent hospitalization within 3 months (90 days) from the date of current admission.

• Immunocompromised state

• Known diagnosis of malignancy and ongoing chemotherapy or radiotherapy as there is evidence that antioxidant supplement before and during treatment was associated with an increased hazard of recurrence

• Known diagnosis of malignancy who had completed chemotherapy or radiotherapy with absolute neutrophil count =100 cells/mm3

• Known diagnosis of Stage 4 and above chronic kidney disease (GFR <30 ml/min/1.73m2) and end-stage renal disease on regular dialysis (including peritoneal dialysis or hemodialysis)

• Known history of renal transplantation

• Absence of family members or next of kin for informed consent

Related Conditions & MeSH terms

• Pneumonia

Intervention

Drug:
• Active Ingredient
IV Vitamin C (12g/day)
• Placebo
IV dextrose 5%

Locations

Country	Name	City	State
Malaysia	Hospital Sultanah Bahiyah	Alor Setar	Kedah
Malaysia	Hospital Raja Permaisuri Bainun	Ipoh	Perak
Malaysia	Hospital Raja Perempuan Zainab II	Kota Bharu	Kelantan

Sponsors (2)

Lead Sponsor	Collaborator
Clinical Research Centre, Malaysia	Ain Medicare Sdn Bhd

Country where clinical trial is conducted

Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ventilation-free days (VFD) at 28-days	Unit of measurement: Ventilation-free days	First 28 days after start of randomization
Secondary	Subdistribution hazard ratio of ventilation-free event with mortality as the competing event	Unit of measurement: Cumulative incidence curve, Subdistribution hazard ratio	First 28 days after start of randomization
Secondary	Sequential Organ Failure Assessment (SOFA) score	Unit of measurement: Point score	Baseline, Day 4, Post intervention
Secondary	Plasma C-reactive protein (CRP) level	Unit of measurement: mg/L	Baseline, Day 4, Post intervention
Secondary	28-day vasopressor-free days	Unit of measurement: Vasopressor-free day	First 28 days after start of randomization
Secondary	28-day intensive care unit-free days	Unit of measurement: ICU-free days	First 28 days after start of randomization
Secondary	60-day hospitalization-free days	Unit of measurement: Hospitalization-free days	First 60 days after start of randomization
Secondary	All-cause mortality rates at 28-day	Unit of measurement: Proportion, Percentage	First 28 days after start of randomization
Secondary	Barthel index of activities of daily living	Unit of measurement: Point score	Baseline, Day 60
Secondary	Plasma ascorbate levels	Unit of measurement: µM	Baseline, Day 2 (Between 8th and 9th dose OR Between 9th and 10th dose)